Annual Securities Report — FY2025
What WAKAMOTO PHARMACEUTICAL CO.,LTD. reported for the period from 2025-04-01 to 2026-03-31. Filed by わかもと製薬株式会社
Filed 2026-06-18View the original on EDINET
How much it says
59Typical
What moved here
17named for the first time
Its own wording
44terms
Which filing this is
35/ 35newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
During the fiscal year, revenue increased, and operating income, ordinary income and net income were all positive. The filing also states that the Company made capital investments at facilities including the Sagami-Oi Plant, recorded R&D expenses and advanced the launch of medical devices and products in the ophthalmology field, including multifocal intraocular lenses.
Komori's summary of this document, not the document's own words.59Typical
How much this filing saysA weighted roll-up of 11 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 37 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
76
Very detailed
68
Detailed
46
Typical
75
Very detailed
100
Very detailed
0
Almost nothing
27
Almost nothing
69
Detailed
60
Detailed
55
Typical
73
Detailed
R&D spend4,787億円Money spent making new things.
Cash left over-13億円Cash from the business, less what went into equipment.
Spent on equipment4億円Plants, machines — things meant to last.
Employees303Headcount at the end of this period.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.